Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2000-03-07
2003-09-16
Achutamurthy, Ponnathapu (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S069100, C435S226000, C435S252330, C536S023200, C536S023500, C536S024100
Reexamination Certificate
active
06620606
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to nucleic acid and amino acid sequences of a new human cathepsin and to the use of these sequences in the diagnosis, prevention, and treatment of disorders associated with cell proliferation.
BACKGROUND OF THE INVENTION
Cathepsins are a family of lysosomal proteases which include the cysteine protease cathepsins B, H, K, L, O2, and S. These enzymes have a role in processes that involve proteolysis and turnover of specific proteins and tissues in local microenvironments. Cathepsins also initiate proteolytic cascades by proenzyme activation, participate in the expression of functional MHC class II molecules which bind antigenic peptides, and process antigen in antigen-presenting cells. The various members of this family are differentially expressed, and cathepsin L is closely associated with monocytes, macrophages, and other cells of the immune system. The secreted forms of several members of this family function in tissue remodeling through degradation of collagen, laminin, elastin, and other structural proteins and are implicated in inflammation associated with immunological response and in metastasis (Huisman, W. et al. (1974) Biochem. Biophys. Acta 370:297-307; Mizuochi, T. (1994) Immunol. Lett. 43:189-193; and Baldwin, E. T. (1993) Proc. Natl. Acad. Sci. 90:6796-6800).
The various cathepsin proteases differ in their gene structures and in their transcriptional regulation. The cathepsin L gene promoter has no TATA box but includes several SP-1 sites, two AP-2 transcription regulatory element binding sites, and a cAMP response element. Experimental data confirm that expression of cathepsin L is induced by malignant transformation, growth factors, tumor promoters, and cyclic AMP (Troen, B. et al. (1991) Cell Growth Differ. 2:23-31).
Abnormal regulation and expression of cathepsins is evident in various inflammatory disease states. In cells isolated from inflamed synovia, the mRNA for stromelysin, cytokines, TIMP-1, cathepsin, gelatinase, and other molecules is preferentially expressed. Expression of cathepsins L and D is elevated in synovial tissues from patients with rheumatoid arthritis and osteoarthritis. Cathepsin L expression may also contribute to the influx of mononuclear cells which exacerbates the destruction of the rheumatoid synovium (Keyszer, G. M. (1995) Arthritis Rheum. 38:976-984).
The cathepsins are implicated in several other immune responses. In a rat model of human glomerular disease, the administration of a specific, irreversible inhibitor of cysteine protease (trans-epoxysuccinyl-L-leucylamido-(3-methyl)butane) significantly reduced proteinuria (Baricos, W. H. (1991) Arch. Biochem. Biophys. 288:468-72). The platelet aggregating cysteine protease implicated in thrombotic thrombocytopenic purpura shows the characteristics of a lysosomal cathepsin (Consonni, R. (1994) Br. J. Hematol. 87:321-324). In addition, the increased expression and differential regulation of the cathepsins is linked to the metastatic potential of a variety of cancers and as such is of therapeutic and prognostic interest (Chambers, A. F. et al. (1993) Crit. Rev. Oncog. 4:95-114).
The discovery of a new human cathepsin and the polynucleotides encoding it satisfies a need in the art by providing compositions which are useful in the diagnosis, prevention and treatment of disorders associated with cell proliferation.
SUMMARY OF THE INVENTION
The invention features a substantially purified polypeptide, a new human cathepsin (LCAP), having the amino acid sequence shown in SEQ ID NO:1, or fragments thereof.
The invention further provides an isolated and substantially purified polynucleotide sequence encoding the polypeptide comprising the amino acid sequence of SEQ ID NO:1 or fragments thereof and a composition comprising said polynucleotide sequence. The invention also provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence encoding the amino acid sequence SEQ ID NO:1, or fragments of said polynucleotide sequence. The invention further provides a polynucleotide sequence comprising the complement of the polynucleotide sequence encoding the amino acid sequence of SEQ ID NO:1, or fragments or variants of said polynucleotide sequence.
The invention also provides an isolated and purified sequence comprising SEQ ID NO.2 or variants thereof. In addition, the invention provides a polynucleotide sequence which hybridizes under stringent conditions to the polynucleotide sequence of SEQ ID NO:2.
In another aspect the invention provides a composition comprising an isolated and purified polynucleotide sequence comprising the complement of SEQ ID NO:2, or fragments or variants thereof. The invention also provides a polynucleotide sequence comprising the complement of SEQ ID NO:2.
The present invention further provides an expression vector containing at least a fragment of any of the claimed polynucleotide sequences. In yet another aspect, the expression vector containing the polynucleotide sequence is contained within a host cell.
The invention also provides a method for producing a polypeptide comprising the amino acid sequence of SEQ ID NO:1 or a fragment thereof, the method comprising the steps of: a) culturing the host cell containing an expression vector containing at least a fragment of the polynucleotide sequence encoding LCAP under conditions suitable for the expression of the polypeptide; and b) recovering the polypeptide from the host cell culture.
The invention also provides a pharmaceutical composition comprising a substantially purified LCAP having the amino acid sequence of SEQ ID NO:1 in conjunction with a suitable pharmaceutical carrier.
The invention also provides a purified antagonist which decreases the activity of a polypeptide of SEQ ID NO:1. In one aspect the invention provides a purified antibody which binds to a polypeptide comprising at least a fragment of the amino acid sequence of SEQ ID NO:1.
Still further, the invention provides a purified agonist which modulates the activity of the polypeptide of SEQ ID NO:1.
The invention also provides a method for treating or preventing a cancer comprising administering to a subject in need of such treatment an effective amount of an antagonist which decreases the activity of LCAP.
The invention also provides a method for treating or preventing an immune response comprising administering to a subject in need of such treatment an effective amount of an antagonist which decreases the activity of LCAP.
The invention also provides a method for detecting a polynucleotide which encodes LCAP in a biological sample comprising the steps of: a) hybridizing a polynucleotide sequence complementary to the polynucleotide encoding SEQ ID NO:1 to nucleic acid material of a biological sample, thereby forming a hybridization complex; and b) detecting the hybridization complex, wherein the presence of the complex correlates with the presence of a polynucleotide encoding LCAP in the biological sample. In a preferred embodiment, prior to hybridization, the nucleic acid material of the biological sample is amplified by the polymerase chain reaction.
REFERENCES:
Hillier et al. Homo sapiens cathepsin L precursor mRNA sequence. GenBank Accession AA235364. Mar. 3, 1997.*
Huisman, W. et al., “Role of Individual Cathepsins In Lysosomal Protein Digestion As Tested By Specific Inhibitors”,Biochimica et Biophysica Acta, 370: 297-307 (1974).
Mizuochi, T. et al., “Both cathepsin B and cathepsin D are necessary for processing of ovalbumin as well as for degradation of class II MHC invariant chain”,Immunol. Lett., 43: 189-193 (1994).
Baldwin, E.T. et al., “Crystal structures of native and inhibited forms of human cathepsin D: Implications for lysosomal targeting and drug design”,Proc. Natl. Acad. Sci. USA, 90: 6796-6800 (1993).
Troen, B.R. et al.,“Downstream Sequences Mediate Induction of the Mouse Cathepsin L Promoter by Phorbol Esters”,Cell Growth Differ., 2: 23-31 (1991).
Keyszer, G.M. et al., “Comparative Analysis Of Cathepsin L, Cathepsin D, And Collagenase Messenger RN
Bandman Olga
Corley Neil C.
Guegler Karl J.
Shah Purvi
Achutamurthy Ponnathapu
Fronda Christian L.
Incyte Corporation
Incyte Corporation
LandOfFree
Human cathepsin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human cathepsin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human cathepsin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3042325